about
Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to seleniumEarly Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature MouseSelective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injuryFas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.Library synthesis, screening, and discovery of modified Zinc(II)-Bis(dipicolylamine) probe for enhanced molecular imaging of cell death.Selective water-soluble gelatinase inhibitor prodrugs.Characterization of the anti-inflammatory Lactobacillus reuteri BM36301 and its probiotic benefits on aged miceDiscovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-oneSynergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrierStructure-Activity Relationship for the 4(3H)-Quinazolinone AntibacterialsPhenoxide-Bridged Zinc(II)-Bis(dipicolylamine) Probes for Molecular Imaging of Cell Death.Water-soluble mmp-9 inhibitor prodrug generates active metabolites that cross the blood-brain barrierTissue vaccines for cancer.ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivoO-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.A chemical biological strategy to facilitate diabetic wound healing.Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity.Cancer vaccines: harnessing the potential of anti-tumor immunity.Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma.Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury.Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.In vivo cell death mediated by synthetic ion channelsMethylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces.Noninvasive optical imaging of staphylococcus aureus bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity group conjugated to a near-infrared fluorophore.Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.Susceptibility of Lobund-Wistar x Copenhagen hybrid rats to autochthonous prostate carcinogenesis.Structure-activity relationship for the oxadiazole class of antibiotics.Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts.In vivo targeting of cell death using a synthetic fluorescent molecular probeAddition of nimesulide to small intestinal submucosa biomaterial inhibits postsurgical adhesiogenesis in rats.Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.Comparison of the host ranges and antigenicity of Cryptosporidium parvum and Cryptosporidium wrairi from guinea pigs.Derivation of Pasteurella multocida-free rabbit litters by enrofloxacin treatment.Immunization of rabbits against a bacterial pathogen with an alginate microparticle vaccine.Evaluation of hypothermia-induced analgesia and influence of opioid antagonists in leopard frogs (Rana pipiens).The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
P50
Q24805093-C1C100EB-A40B-453B-AADD-53FE1B5323E9Q27340373-580337BB-4B34-4523-93DF-6CBE68192596Q28534597-7557C528-923D-470D-B524-90045F2768CAQ33530092-9CD33618-5954-4E52-9307-049A261F8976Q35103904-898108EF-AEA5-48F1-A27B-81C734D8AD3FQ35308826-C8D80CE2-75C8-4C1A-80D3-927A6368E5E4Q35994281-CEF6C9B3-A7E0-4C23-8FB9-C449BBF16692Q36165366-642C6E84-A456-4B1D-BFD4-997DF1990B37Q36200010-6A92BD30-055D-44C7-B25D-748DCEC376D7Q36326852-D6F9E4C1-AAE4-4C95-959E-035877C6F009Q36947075-F77936E3-AD7C-45E0-A704-59BCCCD43D7AQ37030890-25C23D2F-FD5C-427A-8CA0-F090F21E2D65Q37113839-7DC12E88-19B2-46BE-A18F-EA7439C9D64EQ37123446-066B67A5-8B05-411A-939C-84BD21259FCFQ37142879-2C41A199-0286-4020-A691-7128E05103D1Q37432524-19205E36-FB1D-4129-81C6-46E093C9E724Q37625582-8A38F22A-F6A0-4FF1-9269-C3606F48243EQ37701333-B9708198-7C31-485B-8141-5799F5F081A7Q38121282-381935D9-F0B3-4A62-8939-B1CD1EADC5A0Q38769892-339E59DF-1FC9-4A98-AED1-BB8D73AEFC14Q38846432-60460701-9421-4E2D-A371-C09CDF4BF159Q38948139-4D610ACE-93D5-48A7-BDB5-39EED60015B6Q38988367-77CE2DF6-CB86-48ED-A696-49B10491BA0AQ39308077-846DDACA-5080-4188-913A-A5DBC605DFEDQ39557196-29CA51CC-6C12-48E4-A313-5CAA2FD32963Q39762666-74C1B49F-EE23-4376-ABFC-77E3FDBECCDAQ39982027-D837DC94-7F21-4DF3-BF61-3AEBE6121BE1Q40180119-AB9F6DC0-CD24-4FA5-BFEE-9DA9E36C2827Q40235539-0DD17801-0C25-4786-8D22-FB057B49BCCFQ40458167-8FA4BEDE-AAEF-4795-B202-5F890BE20BC8Q41543426-B690273A-5332-4F01-AA08-66B2CAF3B30CQ42592608-9DCABEB4-38DA-4465-A7C5-C4A8FE4E034BQ42843539-035A6E57-A853-4412-9E44-9B3EBABAEC0FQ43187334-3E1A2D83-EFB7-4419-B8D7-CAEA6ED3C2ABQ43240660-CE586C78-F408-41EE-8C7E-E125EE8FFFA7Q43704274-DE532F5F-D268-436F-8BAC-DADE74F058E9Q44032403-9C9EC425-83BF-47DE-A9D8-05F98A01351EQ44247829-17D5DD7E-B2DC-45BB-9679-B3D922C56898Q44352098-505C5A1E-877B-4FEA-AEC5-A767F9BF413EQ44907488-A011B924-DD1F-4A46-9825-BFA4632FB465
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark A. Suckow
@ast
Mark A. Suckow
@en
Mark A. Suckow
@es
Mark A. Suckow
@nl
Mark A. Suckow
@sl
type
label
Mark A. Suckow
@ast
Mark A. Suckow
@en
Mark A. Suckow
@es
Mark A. Suckow
@nl
Mark A. Suckow
@sl
prefLabel
Mark A. Suckow
@ast
Mark A. Suckow
@en
Mark A. Suckow
@es
Mark A. Suckow
@nl
Mark A. Suckow
@sl
P108
P106
P1153
7006456116
P21
P31
P496
0000-0001-7317-697X